Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome
Open accessThe DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) is a chronic complex inflammatory gut pathological condition, examples of which include Crohn’s disease (CD) and ulcerative colitis (UC), which is associated with significant morbidity. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The gut microbiota acts as a metabolic organ and contributes to human health by performing various physiological functions; deviation in the gut flora composition is involved in various disease pathologies, including IBD. This review aims to summarize the current knowledge of gut microbiota alteration in IBD and how this contributes to intestinal inflammation, as well as explore the potential role of gut microbiota-based treatment approaches for the prevention and treatment of IBD. The current literature has clearly demonstrated a perturbation of the gut microbiota in IBD patients and mice colitis models, but a clear causal link of cause and effect has not yet been presented. In addition, gut microbiota-based therapeutic approaches have also shown good evidence of their effects in the amelioration of colitis in animal models (mice) and IBD patients, which indicates that gut flora might be a new promising therapeutic target for the treatment of IBD. However, insufficient data and confusing results from previous studies have led to a failure to define a core microbiome associated with IBD and the hidden mechanism of pathogenesis, which suggests that well-designed randomized control trials and mouse models are required for further research. In addition, a better understanding of this ecosystem will also determine the role of prebiotics and probiotics as therapeutic agents in the management of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in sex hormones levels may lead to microbial dysbiosis which has been previously implicated in IBD and its symptom severity.(40)”
From Association Between Sex Hormone Levels and Gut Microbiota Composition and Diversity—A Systematic Review (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 3×
“25% (fewer) of the mucosal microbial genes of healthy individuals [25].”
BackgroundInfluentialChanges of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087 · cited 1×
“The highest incidence rate has been recorded in developed countries, such as North America, Europe, Australia, and New Zealand [6], while recently, IBD has been gradually becoming more common in developing areas such as Asia and South America, and in developing countries such as including Brazil, South Korea, and Chin…”
BackgroundAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 2×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDe Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 1×
“Human Bacteroidetes Firmicutes, Enterobacteriaceae Decrease Increase [163]”
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030 · cited 1×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDiarrheagenic Escherichia coli
Nataro, J. P., & Kaper, J. B. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.1.142 · Cited by 5,006 · cited 1×
“Many studies in human IBD patients have reported the commensal bacteria association with the patient’s intestines; for example, an association of adherent/invasive Escherichia coli (AIEC), a normal gut flora of the Enterobacteriaceae group, has been found with CD [121].”
BackgroundMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“In addition, certain symbiotic gut microbiota members have been reported to have distinct and specific effects on the host immune system, and are considered key to immune homeostasis [31,37,38].”
BackgroundHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 1×
“Genome-wide association studies (GWAS) have identified more than 160 genetic loci associated with conferring protection from IBD or increased risk to IBD development [172].”
BackgroundRichness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Research works printed but not linked: 2
- Zhang, 2007, Wumei pill decoction in the treatment of 72 cases of chronic nonspecific ulcerative colitis, Mod. J. Integr. Tradit. West. Med., 16, 5156
- Yan, 2013, Effect of Astragalus Polysaccharides on Th17/Treg Cytokines and Pulmonary Inflammation in Asthmatic Rats, Chin. Pharmacol. Bull., 29, 1275
Cited by
Items 401–500 of 804
Xiong, M., Liu, Z., Wang, B., Sokolich, T., Graham, N. M., Chen, M., Wang, W.-L., & Boldin, M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315944121 · Cited by 12
Liao, Y., Wu, S., Zhou, G., Mei, S., Ou, B., Wen, M., Yang, Y., & Wen, G. (2024) · Journal of Proteomics · doi:10.1016/j.jprot.2024.105360 · Cited by 13
A human gut bacterium antagonizes neighboring bacteria by altering their protein-folding ability
Lim, B., Xu, J., Wierzbicki, I. H., Gonzalez, C. G., Chen, Z., Gonzalez, D. J., Gao, X., & Goodman, A. L. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.01.008 · Cited by 13
Zhu, Y., He, D., Gao, X., Wang, A., Yu, J., Wang, S., Cui, B., Mu, G., Ma, C., & Tuo, Y. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c13044 · Cited by 12
Gut Microbiota and COVID-19: Unraveling the Gut–Lung Axis and Immunomodulatory Therapies
Alves, M. J. V., Rego, M. S., da Silva, R. C. C., Silva, R. D. A., Arruda, I. E. S., Júnior, S. D. S. L. P., & Balbino, V. D. Q. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00250 · Cited by 12
Popov, J., Caputi, V., Nandeesha, N., Rodriguez, D. A., & Pai, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111365 · Cited by 97
Im, Y., Wang, Q., Park, J., Lee, H., & Kim, H. (2023) · Applied Sciences · doi:10.3390/app13031742 · Cited by 12
Zaharie, R. D., Vălean, D., Popa, C., Fetti, A. C., Zdrehuş, C., Puia, A., Usatiuc, L. O., Schlanger, D., & Zaharie, F. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043472 · Cited by 12
Incorporating plasmid biology and metagenomics into a holistic model of the human gut microbiome
Stockdale, S. R., & Hill, C. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102307 · Cited by 13
Xu, C., Zhao, L., Zhou, W., Li, Y., Hu, H., & Wang, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111009 · Cited by 14
Liu, Y., Robinson, A. M., Su, X. Q., & Nurgali, K. (2024) · Biomolecules · doi:10.3390/biom14040447 · Cited by 12
Niu, K., Li, Q., Liu, Y., Qiao, Y., Li, B., Wei, C., Wang, K., Cui, L., Zheng, C., Wang, R., et al. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9929093 · Cited by 12
Li, C.-X., Wang, Y., Zhang, W., Zhang, S., Li, J., Zhou, T., Duan, J., & Guo, J. (2023) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x23500696 · Cited by 13
Intercellular adhesion molecule 1 and selectin l play crucial roles in ulcerative colitis
He, J., Ni, Z., & Li, Z. (2023) · Medicine · doi:10.1097/md.0000000000036552 · Cited by 11
Lee, K.-I., Jo, Y., Yuk, H. J., Kim, S., Kim, H., Kim, H. J., Hwang, S.-K., & Park, K.-S. (2024) · Antioxidants · doi:10.3390/antiox13030340 · Cited by 13
“The gut microbiome plays a crucial role in the pathology of numerous intestinal diseases, including IBD [27].”
Jha, M., Waheed, A., Hooti, J. A., Nair, S., Najam, A., Mal, M. M., Tummala, N., Shariq, A. S., Hurairah, A., & Daniel, M. G. (2025) · Health Science Reports · doi:10.1002/hsr2.71157 · Cited by 11
Potential Modulatory Microbiome Therapies for Prevention or Treatment of Inflammatory Bowel Diseases
Bunt, D. V., Minnaard, A. J., & Aidy, S. E. (2021) · Pharmaceuticals · doi:10.3390/ph14060506 · Cited by 14
Zajączkowska, Ż., Akutko, K., Kváč, M., Sak, B., Szydłowicz, M., Hendrich, A. B., Iwańczak, B. M., & Kicia, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.741751 · Cited by 11
“Although the aetiology of IBD is still poorly understood, the role of the gut microbiota combined with genetic susceptibility in disease pathogenesis is highlighted (1).”
BackgroundEl‐Deeb, O. S., El‐Esawy, R. O., Alshenawy, H. A., & Ghanem, H. B. (2022) · Redox Report · doi:10.1080/13510002.2022.2046425 · Cited by 11
Interactions between Medications and the Gut Microbiome in Inflammatory Bowel Disease
Eckenberger, J., Butler, J. C., Bernstein, C. N., Shanahan, F., & Claesson, M. J. (2022) · Microorganisms · doi:10.3390/microorganisms10101963 · Cited by 14
“This may be due to the heterogeneity of IBD and/or variations in study design and patient populations [3].”
BackgroundInfluentialImpact of Environmental and Pharmacologic Changes on the Upper Gastrointestinal Microbiome
Bilello, J. L., & Okereke, I. C. (2021) · Biomedicines · doi:10.3390/biomedicines9060617 · Cited by 11
Wang, J., Mao, T., Zhou, H., Jiang, X., Zhao, Z., & Zhang, X. (2024) · Medicine · doi:10.1097/md.0000000000037095 · Cited by 10
“[24] Specific bacteria like Bifidobacterium and Akkermansia decrease, while harmful species increase, potentially damaging the intestinal mucosal barrier and worsening inflammation.”
BackgroundZhou, J., Wang, J., Jiajing, W. A. N. G., Li, D., Hou, J., Li, J., Bai, Y.-E., & Gao, J. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60556-x · Cited by 22
Self-citationWang, J., Guo, Z., Shen, M., Xie, Q., & Xiang, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366489 · Cited by 11
Nori, W., Al-kaabi, M. M., Akram, N. N., Kassim, M. A. K., & Pantazi, A. C. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673314861240429072352 · Cited by 12
Yadav, P., & Chauhan, N. S. (2024) · Biocell · doi:10.32604/biocell.2024.051318 · Cited by 11
“These alterations ultimately lead to chronic gut in fl ammation, as observed in patients suffering from IBD [151].”
BackgroundSharma, N., Tewatia, P., Harvey, P., & Kumar, A. (2024) · Diagnostics · doi:10.3390/diagnostics14192112 · Cited by 10
Sangfuang, N., McCoubrey, L. E., Awad, A., Marzorati, M., Ghyselinck, J., Verstrepen, L., Munck, J. D., Medts, J. D., Gaisford, S., & Basit, A. W. (2025) · Translational research · doi:10.1016/j.trsl.2025.02.004 · Cited by 11
Role of Pyroptosis in inflammatory bowel disease
Xiao, Z., Xie, J., Zhao, X., Chen, X., Lu, Y., Xu, Y., Wu, M., An, L., & Li, Q. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114619 · Cited by 12
Inflammatory bowel disease in paediatrics: Navigating the old challenges and emerging frontiers
Al‐Beltagi, M., Saeed, N. K., Mani, P. K. C., Bediwy, A. S., & Elbeltagi, R. M. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i35.111934 · Cited by 14
“Some monogenic forms, for example, may be curable with hematopoietic stem cell transplantation, a treatment not usually considered in conventional IBD[84].”
InfluentialThe gut immune axis in ulcerative colitis: insights from microbiome research
Wasim, R. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11124-8 · Cited by 11
Targeted therapeutics for IBD unraveling the potential of stimulus-responsive nanoparticles
Barros, A. S., Nunes, R., & Sarmento, B. F. C. C. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114466 · Cited by 14
Role of Gut Microbiome and Enteric Bacteria in Gallbladder Cancer
Sharma, J., Huda, F., Naithani, M., Singh, S. K., Kumar, N., & Basu, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104404 · Cited by 12
Causal Effects of Blood Lipid Traits on Inflammatory Bowel Diseases: A Mendelian Randomization Study
Yao, Z., Jiang, F., Luo, H., Zhou, J., Shi, W., Xu, S., Zhang, Y., Dai, F., Li, X., Liu, Z., et al. (2023) · Metabolites · doi:10.3390/metabo13060730 · Cited by 10
Nobakht, N. A. A., Lashgari, N., Roudsari, N. M., Niknejad, A., Khayatan, D., Tavakoli, S., Abdollahi, A. R., Esmaealzadeh, N., Momtaz, S., & Abdolghaffari, A. H. (2023) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523022666230825105223 · Cited by 9
Lauko, S., Gancarčíková, S., Hrčková, G., Hajdučková, V., Andrejčáková, Z., Fecskeová, L. K., Bertková, I., Hijová, E., Kamlárová, A., Janíčko, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines12010043 · Cited by 10
“A decrease in the diversity [1] and proportions [73] of commensal bacteria, particularly representatives of the strains Firmicutes and Bacteroidetes, is a sign of dysbiosis.”
BackgroundInfluentialLi, J., Wang, X., Wang, Q., Hu, Y., Wang, S., Xu, J., & Ye, J. (2024) · Veterinary Research · doi:10.1186/s13567-023-01262-x · Cited by 11
Li, A., Liu, A., Wang, J., Song, H., Luo, P., Zhan, M., Zhou, X., Chen, L., & Zhang, L. (2024) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.13410 · Cited by 10
Gut–Oral Microbial Dysbiosis: A Correlated Ecosystem
Siddiqui, Z. R., Rahman, S., Verma, N., Srivastava, A. K., Jahan, N., Mohanty, S., & Suman, S. (2025) · Advanced Gut & Microbiome Research · doi:10.1155/agm3/7351229 · Cited by 12
“However, there is ongoing debate about whether these changes in microbiota are a cause of IBD or merely a consequence of the disease ’ s pathological alterations [78].”
Zhong, L., Yang, F., Gan, L., Yang, Z., Tian, S., Huang, M.-Q., Lv, C., & Huang, L. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/1395954 · Cited by 10
“)ese changes lead to accelerated proliferation and transport of colonic epithelial cells, followed by dysplasia and cancer [37].”
BackgroundThe Aging Bowel Dysfunction and Elderly Vulnerability towards COVID-19 Infection
Lerner, A., & McCarty, M. F. (2021) · Life · doi:10.3390/life11020097 · Cited by 11
Zhao, S., Zhu, L., Feng, W., Zhang, L., Chen, D., Hu, Y.-C., & Shen, H. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10808 · Cited by 10
Umar, M., Muzammil, S., Zahoor, M. A., Mustafa, S., Ashraf, A., Hayat, S., & Ijaz, M. U. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1005255 · Cited by 11
“Based on docking fitness and GOLD score, the ranking order of receptor proteins with fisetin compound is superoxide dismutase, interleukin, aspartate aminotransferase, alkaline phosphatase, TNF-alpha, alanine transaminase, cyclo-oxygenase 2, antiapoptotic, and glutathione reductase.”
BackgroundInfluentialLong, D., Alghoul, Z., Sung, J. J., Yang, C., & Merlin, D. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2231345 · Cited by 10
“Accumulating evidence indicates that disturbance of the intestinal microbiota can directly impact the progression of IBD and CAC [49,50].”
BackgroundAkter, S., Tasnim, S., Barua, R., Choubey, M., Arbee, S., Mohib, M. M., Minhaz, N., Choudhury, A., Sarker, P., & Mohiuddin, M. S. (2023) · Gastrointestinal Disorders · doi:10.3390/gidisord5030028 · Cited by 10
Microbes with higher metabolic independence are enriched in human gut microbiomes under stressPreprint
Veseli, I., Chen, Y. T., Schechter, M. S., Vanni, C., Fogarty, E. C., Watson, A. R., Jabrì, B., Blekhman, R., Willis, A. D., Yu, M., et al. (2023) · eLife · doi:10.7554/elife.89862.1 · Cited by 19
Li, S., Wu, T., Wu, J., Chen, W., & Zhang, D. (2024) · Drug Delivery · doi:10.1080/10717544.2024.2415580 · Cited by 10
“Dysbiosis leads to changes in gut microbiota-related functions, such as changes in fermentation products; dysbiosis affects functions such as the maintenance of gut barrier integrity, and gut homeostasis (Khan et al., 2019).”
BackgroundAzari, H., George, M., & Albracht‐Schulte, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312836 · Cited by 10
“…the diversity, richness, evenness, and ratios of specific bacterial phyla and their metabolites results in dysbiosis and contribute to a variety of pathologies [34,35] via changes in the concentrations of vitamins and SCFAs, changes in immune responses, and the growth of pathogenic bacteria [30].”
Bonazzi, E., Barba, C. D., Lorenzon, G., Maniero, D., Bertin, L., Barberio, B., Facciotti, F., Caprioli, F., Scaldaferri, F., Zingone, F., et al. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2495087 · Cited by 9
“Several studies are trying to unravel the exact mechanisms by which the gut microbiota could participate in the pathophysiology and the development of the disease [26,27].”
Alizadeh, M. A., Wong, U., Siaton, B. C., France, M., Patil, S. A., George, L. A., Hudhud, D. N., Motwani, K. K., Scott, W. H., Raufman, J., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2505114 · Cited by 11
Zeb, F., Osaili, T. M. I., Hashim, M. S., Alkalbani, N. S., Papandreou, D., Ismail, L. C., Naja, F., Radwan, H. M., Hasan, H. A., Obaid, R. S., et al. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf120 · Cited by 10
Vernon‐Roberts, A., & Day, A. S. (2023) · Translational Pediatrics · doi:10.21037/tp-23-35 · Cited by 12
“Both factors contribute to intestinal dysbiosis, and there is a clear consensus on the involvement of the gut microbiome in the development of IBD (100).”
Duan, B., Hu, Q., Ding, F., Huang, F. J., Wang, W., Yin, N., Liu, Z., Zhang, S., Dong-chu, H., & Lu, Q. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23082 · Cited by 9
“TCM , with lower adverse effects [27], has been widely used to treat UC in China [28].”
BackgroundHaiou, W., Li, J., Huang, W., Ye, Y., & Gao, L. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100356 · Cited by 10
Intestinal Flora Imbalance Induced by Antibiotic Use in Rats
Tong, G., Qian, H., Li, D., Li, J., Chen, J., Li, X., & Tan, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s447098 · Cited by 9
Inflammatory Bowel Diseases and the Efficacy of Probiotics as Functional Foods
Vitetta, L., Oldfield, D., & Sali, A. (2024) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1602013 · Cited by 10
“…alterations include a reduced abundance of putatively beneficial taxa (e.g., Akker-mansia muciniphila and Faecalibacterium prausnitzii ) and a higher abundance of putative pathogenic taxa (e.g., Escherichia coli and certain Enterobacteriaceae) as reported across multiple conditions [7,8].”
BackgroundKirindage, K. G. I. S., Jayasinghe, A. M. K., Jang, M., Lee, K.-J., Yun, H.-J., Ahn, G., & Oh, J.-Y. (2024) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2407.07036 · Cited by 10
Xu, D.-Q., Geng, J.-X., Gao, Z.-K., Fan, C.-Y., Zhang, B.-W., Han, X., He, L., Dai, L., Gao, S., Yang, Z., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177533 · Cited by 9
Iwamuro, M., Takahashi, T., Watanabe, N., Tanaka, T., Inokuchi, T., Hiraoka, S., Otsuka, F., & Okada, H. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211051982 · Cited by 9
Zhang, L., Xiong, S., Jin, F., Zhou, F., Zhou, H., Guo, J., Wen, C., & Huang, B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1003905 · Cited by 11
Osmond, M. J., Korthals, E., Zimmermann, C. J., Roth, E. J., Marr, D. W. M., & Neeves, K. B. (2023) · ACS Omega · doi:10.1021/acsomega.3c00886 · Cited by 9
Li, A., Zhang, L., Chen, L., Wang, J., Liu, A., Luo, P., Zhan, M., Zhou, X., Chen, L., & Zhang, J. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105995 · Cited by 10
Chen, J., Xiao, Y., Wang, K., Fu, X., Fan, Y., Hossen, M. J., Chen, Y., Bai, W., Yu, Z., & Xu, B. (2024) · Food Frontiers · doi:10.1002/fft2.344 · Cited by 9
TMAO and the gut microbiome: implications for the CVD-CKD-IBD axis
Kim, S. H., Yoon, M. Y., & Yoon, S. S. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2522324 · Cited by 14
“At the family level, a decrease in beneficial bacteria like Lachnospiraceae and Ruminococcaceae has been reported [81,82].”
Huang, Y., Lin, J., Chen, W., Shia, B., & Wu, S. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf165 · Cited by 8
Wang, C., & Zhan, D. (2025) · IET Systems Biology · doi:10.1049/syb2.70047 · Cited by 8
“These emerging therapeutic strategies include precision dietary modifications, next‐ generation probiotics and prebiotics, faecal microbiota transplantation (FMT) and microbial‐derived metabolites—each showing unique advantages and limitations in paediatric populations [100–102].”
Gut-Microbiome Interactions: Characterization, Therapeutic Implications and Machine Learning
Ayivi-Tosuh, S. M., Dofuor, A. K., Yamoah, J. A. A., Gayi, B. K., Aiduenu, A. F., Akomea, A., Anovunga, S. A., Ekloh, W., & Basing, L. A. (2026) · Sage Open Pathology · doi:10.1177/30502098251415109 · Cited by 8
“170 Microbiome-based therapies for autoimmune conditions include fecal microbiota transplantation, which has shown efficacy in inducing remission in ulcerative colitis.”
Mahnič, A., Pintar, Š., Skok, P., & Rupnik, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.988426 · Cited by 8
The Human Gut Microbiota: A Dynamic Biologic Factory
Minagar, A., & Jabbour, R. (2024) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2023_243 · Cited by 9
Go, Y. G., Wang, Q., Park, J., Lee, H., & Kim, H. (2024) · Applied Sciences · doi:10.3390/app14072835 · Cited by 8
Wang, N., Li, Z., Cao, L., & Cui, Z. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305926 · Cited by 9
Wu, W., Sun, Y., Niu, S., Li, X., Chen, L., Xie, S., Chang, L., Wei, S., Jing, M., Li, H., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8389 · Cited by 9
The antiviral effects and underlying mechanisms of probiotics on viral infections
Javanshir, N., Ebrahimi, V., Mazhary, Z., Jahromi, B. S., Zuo, T., & Fard, N. A. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107377 · Cited by 9
Huang, Y., Yang, C., Fu, B., Guo, H., Chen, Y., & Xu, D. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1494525 · Cited by 10
Ye, X., An, X., Zhang, T., Kong, Y., Jia, S., & Wu, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114547 · Cited by 8
Shitty stories: Experimenting with probiotic participation through design
Lenskjold, T. U., & Wilde, D. (2022) · Proceedings of DRS · doi:10.21606/drs.2022.521 · Cited by 8
Li, X.-H., Liu, L., & Wu, W. (2023) · Mediators of Inflammation · doi:10.1155/2023/4188510 · Cited by 9
“However, an imbalance in the intestinal fl ora leads to a decrease in intestinal immune function and over-stimulation of the intestinal mucosal immune response, which eventually leads to the development of IBD [19].”
BackgroundInfluentialEarley, H., Lennon, G., Coffey, J. C., Winter, D. C., & O’Connell, P. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-86166-6 · Cited by 9
You, C., Jirků, M., Corcoran, D. L., Parker, W., & Jirků‐Pomajbíková, K. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.10.033 · Cited by 9
“However, IBD is not infectious, many patients cannot be treated with fecal therapy, and no core microbiota has been identified for IBD, making it difficult to pinpoint how the microbiota could be a causal factor in pathogenesis [31,32].”
BackgroundEnhanced mucosal mitochondrial function corrects dysbiosis and OXPHOS metabolism in IBDPreprint
Kapur, N., Alam, M. A., Hassan, S. A., Patel, P. H., Wempe, L. A., Bhogoju, S., Goretsky, T., Kim, J. H., Herzog, J., Ge, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.14.584471 · Cited by 9
Microbes with higher metabolic independence are enriched in human gut microbiomes under stressPreprint
Veseli, I., Chen, Y. T., Schechter, M. S., Vanni, C., Fogarty, E. C., Watson, A. R., Jabrì, B., Blekhman, R., Willis, A. D., Yu, M., et al. (2024) · eLife · doi:10.7554/elife.89862.2 · Cited by 10
Rao, N. K., Ghodous, S., Gurram, A., Khorasani, M., Ponnala, M., Habibi, A., Agyeman, K. B., Saberian, P., Biswas, P., Letafatkar, N., et al. (2025) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaf226 · Cited by 9
Kim, G.-S., Chen, K., Xing, Z., Wu, X., Zhang, H., Fang, Y., Zhang, Z., He, N., Li, S., & Zhang, F. (2025) · npj Science of Food · doi:10.1038/s41538-025-00604-7 · Cited by 7
D-allulose alleviates DSS-induced colitis via regulating gut microbiota and bile acid metabolism
Ye, G., Xi, N., Li, G., Wang, Z., Li, Z., Xu, T., Du, F., Dou, G., Zhang, Y., & Liu, J. (2025) · Food Research International · doi:10.1016/j.foodres.2025.117923 · Cited by 9
Baheti, R., Deshkar, S. S., Jadhav, S., Mule, K., Jha, A., Giram, P. S., & Mahore, J. (2026) · Food Research International · doi:10.1016/j.foodres.2026.118598 · Cited by 8
Chen, K., McCulloch, J. A., Neves, R. D., Rodrigues, G. O. L., Hsieh, W., Gong, W., Yoshimura, T., Huang, J., Ó’hUigín, C., Difilippantonio, S., et al. (2023) · Gut Pathogens · doi:10.1186/s13099-023-00557-w · Cited by 8
“The identified E. coli colonies were further cultured on VRBL plates, and single colonies were selected for 16S rRNA gene sequencing to confirm their classification as E. coli (Additional file 1: Fig.”
BackgroundMethodUsman, D., Abubakar, M. B., Ibrahim, K. G., & Imam, M. U. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122328 · Cited by 7
Understanding Microbial Mediation of the Brain-Gut Axis
Horn, J. V., Delgadillo, D. R., & Mayer, E. A. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2024.12.004 · Cited by 7
Upadhyay, K. G., Desai, D., Ashavaid, T. F., & Dherai, A. J. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2491784 · Cited by 7
“Microbial imbalance is well documented in IBD and is known to significantly influence the host’s metabolic pathway [5,6].”
Tubau‐Juni, N., Bassaganya-Riera, J., Leber, A. J., Alva, S. S., & Hontecillas, R. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad124 · Cited by 7
The Anti-Inflammatory Effect of a Probiotic Cocktail in Human Feces Induced-Mouse Model
Salimi, A., Sepehr, A., Hejazifar, N., Talebi, M., Rohani, M., & Pourshafie, M. R. (2023) · Inflammation · doi:10.1007/s10753-023-01870-x · Cited by 9
“The poor therapeutic effect and severe side effects of this treatment have led to the suggestion of other treatments, including the use of prebiotics, pro-biotics, and symbiotic as complementary or alternative medications for the treatment of IBD and other similar diseases [24].”
BackgroundMoradipoor, F., Jivad, N., Asgharzade, S., Zare, E., & Amini-Khoei, H. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23755 · Cited by 8
Complementary and Alternative Medicine in Crohn’s Disease
Seminerio, J. L. (2022) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.12.009 · Cited by 7
Hu, B., He, X., Tan, J., Ma, Y., Wang, G., Liu, S., Li, M., Guo, Y., Sun, R., Sun, M., et al. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.957053 · Cited by 8
Dogra, S., Oneto, C., Sherman, A., Varughese, R., Yuen, A., Sherman, I., Cohen, A., Luo, Y., & Chen, L. A. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001778 · Cited by 7
Preventive effects of Korean red ginseng on experimentally induced colitis and colon carcinogenesis
Shin, H.-J., Kim, D., Zhong, X., Yum, H.-W., Kim, S., Chun, K., Na, H., & Surh, Y. (2020) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2020.04.004 · Cited by 7
Inulin protects against the harmful effects of dietary emulsifiers on mice gut microbiome
Bekar, C., Özmen, Ö., Özkul, C., & Ayaz, A. (2024) · PeerJ · doi:10.7717/peerj.17110 · Cited by 7
“Although the etiology of inflammatory bowel disease is not completely known, alteration in the gut microbiota composition, called dysbiosis, is thought to be an important factor in pathogenesis ( Khan et al., 2019 ).”
BackgroundGhaleb, E., Alioui, Y., Jamalat, Y., Wahan, N., Bashah, A., Al-waqeerah, A., Atta, A., Sun, Y., Xin, Y., Wang, L., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1644325 · Cited by 6
Mingolelli, G., Raherisoanjato, J., Trinh, D., Gao, Y., & Henke, M. T. (2025) · mBio · doi:10.1128/mbio.01523-25 · Cited by 7
“As community structure changes within the gut during dysbiosis, it can trigger inflammation of the surrounding and distant tissue (1).”
Cystic fibrosis and inflammatory bowel disease: parallels in gut physiology and microbiota
Barrack, K. E., & O’Toole, G. A. (2025) · Journal of Bacteriology · doi:10.1128/jb.00167-25 · Cited by 6
“The four well-studied pathogens are Mycobacterium avium paratuberculosis ( MAP ) (94, 95), adherent-invasive E. coli (AIEC) (96–98), Enterococcus faecalis (65, 78), and Clostridium difficile (82, 99, 100).”
Metadata
- Authors
- Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C.
- Affiliations
- Lanzhou University (CN)
- Gansu Key Laboratory of Functional Genomics and Molecular Diagnosis, Lanzhou 730000, China
- Corresponding author
- Zhang, Chunjiang
- Venue
- Pathogens
- Publisher
- MDPI AG
- Published
- 2019-08-13
- Volume
- 8
- Issue
- 3
- Pages
- 126
- ISSN
- 2076-0817 (ISSN-L)
- PMC
- PMC6789542
- OpenAlex
- W2966933380
- Cited by
- 771
- References
- 267
- Citations by year
- 2026: 43 · 2025: 105 · 2024: 149 · 2023: 134 · 2022: 135 · 2021: 132 · 2020: 66 · 2019: 7
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- Lanzhou University Institutional Repository (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Jiangsu Science and Technology Major Project ((No. BA2016036))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- inflammatory bowel disease, gut microbiota, dysbiosis, Crohn's disease, ulcerative colitis, intestinal inflammation, microbiota-based therapy, probiotics, prebiotics, mouse colitis model, IBD pathogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.